Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vargatef

- PMLiVE

Pfizer reports strong data with new breast cancer candidate

Phase II results suggest progression-free survival benefits for PD-0332991

- PMLiVE

Pfizer launches personalised lung cancer drug Xalkori in UK

Becomes first treatment on the market for ALK-positive NSCLC

- PMLiVE

Boehringer launches COPD awareness drive in Japan

Social media campaign will target male smokers’ wives and daughters

- PMLiVE

Astellas seeks FDA approval for personalised Tarceva in lung cancer

Application supported by Roche's EGFR companion diagnostic test

Sanofi reception

Sanofi’s Lyxumia and Zaltrap backed for European approval

Company on course to expand its diabetes and cancer portfolio

- PMLiVE

WHO launches framework to monitor non-communicable diseases

Will measure success of efforts to reduce rates of cancer, diabetes, lung conditions and heart disease

- PMLiVE

Boehringer launches online education portal for hepatitis C

Comes as company moves its interferon-free hep C regimen into phase III

- PMLiVE

NICE rejects Pierre Fabre’s bladder cancer drug Javlor

Says drug received final draft 'no' because pharma company failed to prove efficacy

- PMLiVE

Will Boehringer succeed with Syrum?

Time will tell if Boehringer’s bold ambitions for its Facebook game can be fulfilled

- PMLiVE

Roche’s Avastin cleared in EU for recurrent ovarian cancer

Becomes first biologic to win approval for platinum-sensitive ovarian cancer

- PMLiVE

More action needed to prevent AF-related strokes

Bayer-sponsored report says Europe is heading for a ‘stroke crisis’

- PMLiVE

Boehringer-Lilly win expanded European licence for Trajenta

Type 2 diabetes drug approved as add-on to insulin in adults

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links